KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Inventory (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Inventory for 17 consecutive years, with $740.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory fell 2.54% to $740.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $740.7 million, a 2.54% decrease, with the full-year FY2025 number at $740.7 million, down 2.54% from a year prior.
  • Inventory was $740.7 million for Q4 2025 at Bio-Rad Laboratories, down from $783.2 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $804.3 million in Q3 2024 to a low of $572.2 million in Q4 2021.
  • A 5-year average of $721.0 million and a median of $760.0 million in 2024 define the central range for Inventory.
  • Peak YoY movement for Inventory: decreased 8.04% in 2021, then grew 25.7% in 2022.
  • Bio-Rad Laboratories' Inventory stood at $572.2 million in 2021, then increased by 25.7% to $719.3 million in 2022, then increased by 8.51% to $780.5 million in 2023, then decreased by 2.63% to $760.0 million in 2024, then decreased by 2.54% to $740.7 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Inventory are $740.7 million (Q4 2025), $783.2 million (Q3 2025), and $798.8 million (Q2 2025).